Epilepsy Clinical Trial
— PRECISIONOfficial title:
Precision Radiation Treatment for Epilepsy (PRECISION)
The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery. The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone with the neurologist, radiologist and neurosurgeon. This intervention will make curative-intent treatment possible where this could otherwise not be given and is a non-invasive and non-competitive alternative to epilepsy surgery. It is expected that the health costs for this curative treatment will not exceed standard treatment, such as lifelong medication and neuromodulation.
Status | Not yet recruiting |
Enrollment | 94 |
Est. completion date | January 1, 2028 |
Est. primary completion date | January 1, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years, non-pregnant, written informed consent - The patient or caretaker is able to keep an epilepsy diary - The patient has a diagnosis of epilepsy established by a dedicated Neurologist - The patient had at least 3 focal-onset seizures with impairment of consciousness over a 3-month period despite two or more antiepileptic medication trials - There is sufficient continuous video electroencephalography to determine a unilateral medial temporal seizure focus - There is imaging evidence (i.e. MRI) of the anatomic region to be targeted correlating with the diagnosis of epilepsy - The proposed anatomic region to be targeted aligns with anatomy associated with seizure reduction following focal treatment in literature - A Wada test or a functional MRI to lateralize language has been performed - The patient has completed a standard battery of neuropsychological testing - There is absence of neurological or visual deficits outside of seizure episodes - The patient been deemed an appropriate candidate for stereotactic radiosurgery by a dedicated Radiation Oncologist and Neurosurgeon - Ability to give written informed consent Exclusion Criteria: - Supratentorial abnormalities on brain MRI - Neurological or visual deficits outside of seizure episodes - History of psychiatric diagnoses - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Netherlands | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UVA) | Amsterdam | Noord-Holland |
Netherlands | Maastricht Radiation Oncology | Maastricht | Limburg |
Netherlands | UMC Utrecht | Utrecht |
Lead Sponsor | Collaborator |
---|---|
Maastricht Radiation Oncology | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Maastricht University Medical Center, UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Eekers DBP, Pijnappel EN, Schijns OEMG, Colon A, Hoeben A, Zindler JD, Postma AA, Hoffmann AL, Lambin P, Troost EGC. Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiotherapy adapted Engel classification (RAEC) is I, II or III | Radiotherapy adapted Engel classification (RAEC). For analysis of outcomes in the incidence of seizures, we use in this study the Engel classification, adapted for radiotherapy. This includes four classes: class I - seizure free, class II - rarely seizures, class III improved, more than 75% IV- no significant improvement. | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | Seizure frequency | self-reports and reports from caretakers, combined in a digital diary. | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | Seizure-free days | self-reports and reports from caretakers, combined in a digital diary. | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | Type of epilepsy | self-reports and reports from caretakers, combined in a digital diary. | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | EQ-5D 5 Level (EQ-5D-5L) | EQ-5D-5L is comprised of a descriptive system and a visual analogue scale. The descriptive system measures quality of life along five dimensions, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with five levels for each dimension from which subjects are asked to select one. There are 5 questions and 5 qualitative answers plus a numerical scale (from 0 to 100) related with the general health status. We will attribute a numerical value to the 5 qualitative answers (100 for the best/ 75, 50, 25 and 0 for the worse). | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | The Assessment of Quality of Life-8 Dimensions Score (AQoL-8D Score) | The Assessment of Quality of Life (AQoL) measure of health-related Quality of Life. AQoL-8D covers dimensions of Independent Living, Happiness, Mental Health Coping, Relationships, Self-Worth, Pain, and Senses. Items are scored from 0 to 3. Scores range from 0 to 45 with higher scores indicating poorer quality of life | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | Quality of life in Epilepsy-31 Inventory (QOLIE-31) | The QOLIE includes 31 questions about health and daily activities. Responses are given on a range of scales. Responses are coded to 0 to 100 point scales where higher scores indicate better quality of life. The final score is the average of scores for the individual items. QOLIE-31 is a widely used epilepsy-specific questionnaire |
Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | 'Cost-effectiveness Resource use' is measured with iMTA Productivity Cost Questionnaire (iPCQ) | Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ). The iPCQ is a standardized instrument for measuring and valuing health related productivity losses. This wil be used for the cost effectiveness analysis. | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | 'Cost-effectiveness Resource use' is measured with iMTA Medical Consumption Questionnaire (iMCQ) | Institute for Medical Technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ). The iMCQ is a standardized instrument for measuring medical costs. The aim of the iVICQ is to facilitate and promote an accurate description of providing informal care, its effects on informal caregivers, and how such effects are included in economic evaluations of health care interventions. |
Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | 'Informal care' is meausured with iMTA Valuation of Informal Care Questionnaire (iVICQ) | Institute for Medical Technology Assessment (iMTA) Valuation of Informal Care Questionnaire (iVICQ). The aim of this standardized instrument is to facilitate and promote an accurate description of providing informal care, its effects on informal caregivers, and how such effects are included in economic evaluations of health care interventions. |
Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment | |
Secondary | 'Patients' experiences' are measured with the instrument 'Patient Reported Experience Measures Medical Specialtic Care' (PREM MSZ) Medical Specialistic Care (PREM MSZ) | PREM MSZ is a Dutch standardized questionnaire to report Patient Reported Experience. Instrument is developed by NIVEL (Dutch Institute for Healthcare Research) in collabaration with Dutch healcare insurers. Instrument includes 13 questions about the satisfaction with the communication between the patient and the caregiver, shared decision making, trust in the expertise of the physician, the effect of the treatment. Responses to these questions are coded into 0 to 10 points. Higher scores indicate higher satisfaction with care. In the questionnaire patients are also asked for the evaluation of their own health, recommendations to improve care, and if they would recommend the care to other patients with the same health problem. Finally there are some questions about background variables (age, gender, education) | Baseline (before treatment), 1 year, 2 year, 3 year, 4 year and 5 year after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Completed |
NCT02970396 -
Self-management for People With Epilepsy and a History of Negative Health Events
|
N/A |